John Heymach, MD, PhD
Articles by John Heymach, MD, PhD
Manageable Adverse Effects Associated With Treatments for EGFR+ NSCLC
Published: | Updated:
Practical Implications of the RELAY Trial in EGFR+ NSCLC
Published: | Updated:
John Heymach, MD, reviews the evolving treatment landscape of EGFR+ metastatic non-small cell lung cancer.
Characteristics of Additional KRAS Subsets in Lung Cancer
Published: | Updated:
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses the characteristics of three more KRAS subsets in lung cancer, which researchers discovered in a recent study.
Latest Updated Articles
Improved Outcomes for Patients With EGFR+ NSCLCPublished: May 21st 2020 | Updated: April 27th 2021
Molecular Testing for Newly Diagnosed NSCLCPublished: May 21st 2020 | Updated: April 27th 2021
Repeat Testing at Progression of EGFR+ NSCLCPublished: May 21st 2020 | Updated: April 27th 2021
Treatment Options for EGFR+ NSCLCPublished: May 21st 2020 | Updated: April 27th 2021
Changing Landscape of EGFR+ mNSCLCPublished: May 21st 2020 | Updated: April 27th 2021
Practical Implications of the RELAY Trial in EGFR+ NSCLCPublished: May 21st 2020 | Updated: April 27th 2021